The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000836336
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
10/06/2026
Date registered
Help: Date registered
10/07/2026
Date last updated
Help: Date last updated
10/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
10/07/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Medication Safety Needs Rounds in long-term care facilities: a feasibility study
Scientific title
Medication Safety Needs Rounds: protocol for a mixed methods study to evaluate the feasibility of a multidisciplinary intervention to support quality use of medicines in long-term care facilities
Additional trial identifiers [1] 317099 0
Nil
Universal Trial Number (UTN)
U1111-1341-5394
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Medication-related harm 341637 0
Polypharmacy 341638 0
Medication incidents 341639 0
Dementia 341640 0
Cognitive impairment 341641 0
Falls 341642 0
Hospitalisation 341643 0
Frailty 341644 0
Aging 342289 0
Condition category
Condition code
Public Health 337730 337730 0 0
Health service research
Public Health 337733 337733 0 0
Health promotion/education
Injuries and Accidents 338823 338823 0 0
Other injuries and accidents

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
The Medication Safety Needs Rounds model is an interprofessional approach to improving medication safety in long-term care facilities (LTCFs). Medication Safety Needs Rounds involves a monthly cycle of identifying residents at risk of medication-related harm and conducting a triage meeting to discuss residents’ medication management needs, trigger subsequent actions and develop a plan, and then documenting meeting discussions and implementing follow-up actions. The interprofessional team meetings are designed as a triage meeting to facilitate a brief discussion of residents’ medication management needs among the team and interprofessional collaboration to proactively identify strategies to resolve medication-related issues. We will conduct a non-randomised mixed-methods feasibility study, guided by the Consolidated Framework for Implementation Research and key principles of feasibility studies, to answer the overarching question: ‘Can it work?’.

This study will implement the Medication Safety Needs Rounds intervention across six LTCFs, with each LTCF conducting monthly meetings (approximately 1 hour in duration) for six months (i.e., 36 needs rounds overall).

Each LTCF will be provided with a package of written implementation resources and tools that have been refined during a previous co-design study (1). The research team will provide hard and digital copies of the implementation package to each LTCF team (including the aged care on-site pharmacist, managers, nurses and general medical practitioners where appropriate) at the start of the implementation period. Aged care on-site pharmacists (ACOPs), and other health professionals, will be guided by the triggers identified in the Pocket Guide (provided in the co-designed implementation tools and resources package) to identify and prioritise approximately six to eight residents to discuss at each meeting. The Pocket Guide was informed by existing resources for prioritising individuals for clinical pharmacy services and monitoring medication management in LTCFs and refined during the co-design process. The triggers for identifying residents for discussion in the meeting are focused on changes in resident’s health and wellbeing, medication management issues, recent care transitions, and concerns from the resident, their family or supporters, and other health professionals. Health professionals using the Pocket Guide are expected to use their professional judgement and clinical expertise to screen, identify and select residents for the Medication Safety Needs Rounds meeting.

The research team will work with members of each participating LTCF care team (e.g., managers, nurses, ACOPs, general medical practitioners (GPs)) to provide training and support prior to intervention commencement, and will embed regular opportunities for support and knowledge sharing throughout the study period (e.g., online drop-in sessions, phone and email communications). Training will focus on implementation and data collection processes, individuals’ roles, interprofessional communication/collaboration, communication with residents and their family or supporters, and use of the co-designed written implementation tools and resources. An online workshop (~2 hours) will be available for individuals involved or participating in Medication Safety Needs Rounds at each of the participating sites. An additional online workshop (~1.5 hours) will be available for ACOPs at each participating site. The training will be provided prior to the first Medication Safety Needs Rounds meeting at each site, and will be recorded and made available (together with accompanying slide decks) after the session. Pre-implementation engagement with participating LTCFs (e.g., online meetings and communication over email/telephone) will also develop an implementation plan with each site, including planning for study processes, data collection/reporting, site-specific flexibility, and strategies to engage GPs in needs rounds.

The ACOPs will lead the Medication Safety Needs Rounds process and provide oversight of meeting preparation, documentation and completion of follow-up activities. In Australia, ACOPs are clinical pharmacists credentialled to work on-site in LTCFs. The ACOP role is grounded in provision of person-centred care (e.g., readily available, effective communication and collaboration with residents and supporters) and encompasses activities such as medication management (e.g., medication reconciliation, reviews), clinical governance (e.g., contributions to Medication Advisory Committees or other clinical governance structures), quality use of medicines (e.g., medication information, facility-wide quality improvement, education) and interprofessional communication and collaboration (e.g., multidisciplinary case conferences, care planning). Pre-meeting documentation (e.g., meeting agenda) will be circulated to needs rounds members prior to each meeting. ACOPs will be encouraged to ensure that each resident’s needs and preferences for medication management will be sought prior to the meeting via discussion with the resident and/or their supporter, and to follow-up with them after the meeting to facilitate shared decision-making. Members of the interprofessional Medication Safety Needs Rounds meeting may include the ACOPs, managers, GPs, nurses and personal care workers who administer medications, although the specific structure and representation of various roles and professions may vary between LTCFs (e.g., GP involvement). In each meeting, specific team members will be responsible for chairing the meeting and recording minutes, with guidance provided in the implementation materials. Documentation of action items and follow-up plans will be recorded using the co-designed templates.

Follow-up actions triggered by the Medication Safety Needs Rounds meeting may include, for example, subsequent clinical work or support (e.g., case conference, comprehensive medication review, referral to allied health, specialist care or a support program, advanced care plan, lifestyle and wellbeing support, family meeting), changes to medication regimens (e.g., deprescribing, prescribing, supporting self-administration), staff education, or clinical governance activities (e.g., drug use evaluation, audit and feedback). Action plans will be documented after each meeting and followed up at the beginning of the next meeting to support the cyclical nature of the model. The needs rounds model supports the proactive identification and implementation of follow-up actions, interprofessional communication/collaboration, documentation, shared medication knowledge, and communication with residents and their families or supporters about medications.

The model incorporates some flexibility to account for differences in practice between LTCFs and providers and this is reflected in the provision of guidance for some processes rather than specific requirements. Core components of the intervention include oversight and leadership by the ACOP, monthly interprofessional meetings focused on medication safety, and the development and documentation of action plans. Elements of flexibility can include the structure of GP involvement/attendance, documentation and reporting processes, intersection with other team meetings (including palliative care needs rounds), telehealth, and meeting attendees. Acknowledging some flexibility in the delivery between LTCFs ensures that it meets site-specific needs and this will be comprehensively evaluated to inform scale-up. This non-randomised feasibility study involves all participating LTCFs implementing the intervention, thus none are disadvantaged. De-identified documentation and tracking of Medication Safety Needs Rounds activities and resource utilisation data will be collected from each LTCF to assist assessment of adherence and fidelity, together with regular discussions and support between the sites and the research team during implementation.

The description of this intervention adheres to the Better Reporting of Interventions: Template for Intervention Description and Replication (TIDieR) checklist.

1. Hughes, GA, Javanparast, S, Davis, A, Gwilt, I, Yin, H, Little, K, Gutteridge, DS, Sluggett, JK, on behalf of the Medication Safety Needs Rounds Investigator Team. Resource pack to support implementation of Medication Safety Needs Rounds in long-term care facilities. Adelaide: Adelaide University; 2026. doi: https://doi.org/10.25909/32441520
Intervention code [1] 333860 0
Treatment: Other
Description of the comparator or control
No control group.
Control group
Uncontrolled

Outcomes
Primary outcome [1] 345713 0
Process evaluation of feasibility of the intervention. This will be assessed as a composite outcome.
Timepoint [1] 345713 0
The process evaluation will assess implementation during the implementation period and/or immediately post-intervention. Quantitative and qualitative evaluation data will be collected before, during and after implementation (for up to 12 months before and after the implementation period).
Primary outcome [2] 345716 0
Suitability for future testing and scale-up
Timepoint [2] 345716 0
The scalability assessment will assess scalability of the intervention during the implementation period and/or pre- or post-intervention. Quantitative and qualitative evaluation data will be collected before, during and after implementation (for up to 12 months before and after the implementation period).
Secondary outcome [1] 463004 0
Evaluation of intervention outcomes - intervention impact, demand and outcomes of implementation. This will be assessed as a composite outcome.
Timepoint [1] 463004 0
The outcome evaluation will assess implementation during the implementation period and/or immediately post-intervention. Quantitative and qualitative data will be collected before, during and after implementation (for up to 12 months before and after the implementation period).
Secondary outcome [2] 463005 0
Cost of implementation
Timepoint [2] 463005 0
The costing study will assess costs during the implementation period and/or pre- or post-intervention. Data will be collected before, during and after implementation (for up to 12 months before and after the implementation period).

Eligibility
Key inclusion criteria
This intervention will be delivered at the long-term care facility (LTCF) level. This study does not have inclusion criteria at the resident level.

LTCFs will be eligible if they have an aged care on-site pharmacist (ACOP) working in the LTCF for at least 6 months. The ACOP can be employed by the LTCF/long-term care provider, or the community pharmacy, in line with current policy for Australian Government funding that supports this role.

Individuals participating in evaluation activities may include consumers, health professionals, LTCF staff, and other experts in medication management, aged care, research, or policy and/or practice planning and implementation. Individuals must be aged 18 years or over, able to speak English and have sufficient communication skills to share their experiences of providing or receiving care services. LTCF staff will assist the project team to ensure residents invited to participate are medically stable and able to provide informed consent, including verbally if required.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
This intervention will be delivered at the long-term care facility (LTCF) level and does not have exclusion criteria at the resident level.

LTCFs without an aged care on-site pharmacist (ACOP), or where an ACOP has been working on-site for less than 6 months, will be ineligible.

Individuals who are not medically stable and/or are unable to provide informed consent will not be eligible for participation in the evaluation activities.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis
This study aims to develop, implement and evaluate the feasibility of a Medication Safety Needs Rounds model for LTCFs, adapted from the palliative care needs rounds approach. Using a mixed-methods implementation and evaluation design, we will assess the feasibility of Medication Safety Needs Rounds on a small scale across multiple LTCFs, with a particular focus on the intervention acceptability, practicality, adaptation, integration into routine practice, implementation processes, demand, and associated resource requirements. We will also examine preliminary impacts on medication safety knowledge and skills, interprofessional collaboration/communication, and quality use of medicines indicators, while assessing the suitability of proposed outcome measures for future evaluation. A further objective is to evaluate the scalability of Medication Safety Needs Rounds across diverse LTCF contexts.

We will conduct a non-randomised mixed-methods feasibility study, guided by the Consolidated Framework for Implementation Research and key principles of feasibility studies, to answer the overarching question: ‘Can it work?’.

The mixed methods process and outcome evaluation will include 1) document analysis of de-identified Medication Safety Needs Rounds records, 2) qualitative and quantitative data to track needs rounds activities and resource utilisation, 3) quantitative facility-level quality monitoring evaluation (i.e., quality indicator results pre- and post-implementation), 4) pre- and post-implementation survey to examine medication safety knowledge, skills and confidence, person-centred care, interprofessional communication and collaboration, and value and experiences with Medication Safety Needs Rounds implementation, training and support, 5) researcher observations of Medication Safety Needs Rounds, 6) semi-structured interviews and, if required, focus groups, and 7) a cost estimation study. Using the data collected from the process and outcome evaluation and prior co-design process, we will apply the validated Intervention Scalability Assessment Tool (ISAT) and identify contextual factors, barriers and enablers that may influence broader adoption and long-term sustainability, to determine whether refinement of the intervention or implementation strategy is required for future testing and scale-up.

A sample size of six long-term care facilities (LTCFs) is consistent with that of other feasibility trials and needs rounds studies, and is sufficient to evaluate feasibility of the intervention. Researchers will seek to observe at least one needs rounds meeting at each of the six sites. We also aim to invite all team members involved in the implementation of the intervention at the six LTCFs (i.e., approximately 30 individuals in total or until saturation) to participate in an interview and/or focus groups and online survey. We aim to recruit 15-25 participants to attend a scalability workshop, including at least 1 team member from each site, consumers, project investigators and other experts in aged care, research, policy and program implementation.

Quantitative data will be imported into statistical analysis software for analysis, such as SAS version 9.4, (SAS Institute Inc., Cary, NC, USA) or R Statistical Software (Version 4.5.3, R Core Team), and descriptive statistics will summarise findings. Changes in quality indicators and quantitative outcomes of the online survey conducted pre- and post-implementation will be examined using descriptive statistics, chi-square tests, paired t-tests or McNemar’s tests (if paired samples) or regression analyses (e.g., for trends) as appropriate. Complete case analysis will be used for missing data.

Qualitative data, such as transcripts of focus group/interview and workshop audio files, documents, workshop results, researcher observations and free text responses to survey questions, will be imported into NVivo (version 14) qualitative data analysis software as needed. NVivo will be used to manage the data, develop a coding framework and support the analyses. A hybrid approach to thematic analysis using deductive and inductive processes will be employed.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,SA

Funding & Sponsors
Funding source category [1] 321686 0
Government body
Name [1] 321686 0
Department of Health, Disability and Ageing - Medical Research Future Fund
Country [1] 321686 0
Australia
Primary sponsor type
University
Name
Adelaide University
Address
Country
Australia
Secondary sponsor category [1] 324515 0
None
Name [1] 324515 0
Address [1] 324515 0
Country [1] 324515 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320219 0
University of South Australia Human Research Ethics Committee
Ethics committee address [1] 320219 0
Ethics committee country [1] 320219 0
Australia
Date submitted for ethics approval [1] 320219 0
19/09/2025
Approval date [1] 320219 0
26/11/2025
Ethics approval number [1] 320219 0
207326
Ethics committee name [2] 320223 0
Southern Adelaide Clinical Human Research Ethics Committee
Ethics committee address [2] 320223 0
Ethics committee country [2] 320223 0
Australia
Date submitted for ethics approval [2] 320223 0
27/02/2026
Approval date [2] 320223 0
17/04/2026
Ethics approval number [2] 320223 0
2026/HRE00086

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149802 0
Prof Janet Sluggett
Address 149802 0
Adelaide University, GPO Box 2471, Adelaide, South Australia, 5001
Country 149802 0
Australia
Phone 149802 0
+61 8 8128 4055
Fax 149802 0
Email 149802 0
Contact person for public queries
Name 149803 0
Janet Sluggett
Address 149803 0
Adelaide University, GPO Box 2471, Adelaide, South Australia, 5001
Country 149803 0
Australia
Phone 149803 0
+61 8 8128 4055
Fax 149803 0
Email 149803 0
Contact person for scientific queries
Name 149804 0
Janet Sluggett
Address 149804 0
Adelaide University, GPO Box 2471, Adelaide, South Australia, 5001
Country 149804 0
Australia
Phone 149804 0
+61 8 8128 4055
Fax 149804 0
Email 149804 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: The ethical, governance and confidentiality agreements that underpin the planned data collection for this study do not currently allow public sharing of raw data.



What supporting documents are/will be available?

TypeCitationLinkEmailOther DetailsAttachment
Study protocol    Available on publication
Informed consent form    Available on publication of the study protocol pap... [More Details]
Clinical study report    Available on publication


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.